Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial
出版年份 2020 全文链接
标题
Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial
作者
关键词
acute kidney injury, cardiovascular disease, diabetes, estimated glomerular filtration rate, sodium-glucose co-transporter-2 inhibition
出版物
KIDNEY INTERNATIONAL
Volume 99, Issue 3, Pages 750-762
出版商
Elsevier BV
发表日期
2020-11-10
DOI
10.1016/j.kint.2020.10.031
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A metabolomics based molecular pathway analysis for how the SGLT2‐inhibitor dapagliflozin may slow kidney function decline in patients with diabetes
- (2020) Skander Mulder et al. DIABETES OBESITY & METABOLISM
- Use of sodium–glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study
- (2020) Carina Iskander et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Initial Estimated Glomerular Filtration Rate Decline and Long-Term Renal Function During Intensive Antihypertensive Therapy
- (2020) Didier Collard et al. HYPERTENSION
- Luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, preserves renal function irrespective of acute changes in the estimated glomerular filtration rate in Japanese patients with type 2 diabetes
- (2020) Kentaro Kohagura et al. HYPERTENSION RESEARCH
- The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial
- (2020) Erika Opingari et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis from the EMPA-REG OUTCOME® trial indicate empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics
- (2019) Gert J. Mayer et al. KIDNEY INTERNATIONAL
- Renal effects of a sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status
- (2019) Kiyohide Nunoi et al. DIABETES OBESITY & METABOLISM
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial
- (2019) Mark E. Cooper et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care
- (2019) Elisabetta Patorno et al. CIRCULATION
- Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure
- (2019) Javed Butler et al. Circulation-Heart Failure
- The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study
- (2019) Megumi Oshima et al. DIABETOLOGIA
- Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT
- (2019) Srinivasan Beddhu et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Association of Acute Increases in Plasma Creatinine after Renin-Angiotensin Blockade with Subsequent Outcomes
- (2019) Edouard L. Fu et al. Clinical Journal of the American Society of Nephrology
- Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial
- (2019) Stefan D. Anker et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
- (2019) Erik J.M. van Bommel et al. KIDNEY INTERNATIONAL
- Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose‐lowering therapy?
- (2019) Silvio E. Inzucchi et al. DIABETES OBESITY & METABOLISM
- Biological Variability of Estimated GFR and Albuminuria in CKD
- (2018) Sushrut S. Waikar et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease
- (2018) Claire C J Dekkers et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control
- (2018) Silvio E. Inzucchi et al. CIRCULATION
- Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus
- (2018) Toshiaki Ohkuma et al. HYPERTENSION
- Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial
- (2018) Christoph Wanner et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME® trial
- (2018) Takashi Kadowaki et al. Journal of Diabetes Investigation
- Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
- (2018) Peter Ueda et al. BMJ-British Medical Journal
- Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes
- (2017) Catherine M. Clase et al. KIDNEY INTERNATIONAL
- SP259EFFECTS OF EMPAGLIFLOZIN ON RENAL OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL
- (2017) Christoph Wanner et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
- (2017) David Z I Cherney et al. Lancet Diabetes & Endocrinology
- Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
- (2017) Christoph Wanner et al. CIRCULATION
- Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers
- (2016) H. J. L. Heerspink et al. DIABETES OBESITY & METABOLISM
- Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
- (2016) Hiddo J. L. Heerspink et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial
- (2016) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study
- (2013) Anastasia Lesogor et al. EUROPEAN JOURNAL OF HEART FAILURE
- Prognostic Importance of Early Worsening Renal Function After Initiation of Angiotensin-Converting Enzyme Inhibitor Therapy in Patients With Cardiac Dysfunction
- (2011) Jeffrey M. Testani et al. Circulation-Heart Failure
- An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
- (2011) Frank A. Holtkamp et al. KIDNEY INTERNATIONAL
- Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial
- (2011) Marc Evans et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search